PL364825A1 - Pochodne sapogeniny, ich synteza i zastosowanie oraz sposoby oparte na ich zastosowaniu - Google Patents

Pochodne sapogeniny, ich synteza i zastosowanie oraz sposoby oparte na ich zastosowaniu

Info

Publication number
PL364825A1
PL364825A1 PL02364825A PL36482502A PL364825A1 PL 364825 A1 PL364825 A1 PL 364825A1 PL 02364825 A PL02364825 A PL 02364825A PL 36482502 A PL36482502 A PL 36482502A PL 364825 A1 PL364825 A1 PL 364825A1
Authority
PL
Poland
Prior art keywords
synthesis
sapogenin derivatives
sapogenin
derivatives
Prior art date
Application number
PL02364825A
Other languages
English (en)
Inventor
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Original Assignee
Phytotech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotech Limited filed Critical Phytotech Limited
Publication of PL364825A1 publication Critical patent/PL364825A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL02364825A 2001-03-28 2002-03-28 Pochodne sapogeniny, ich synteza i zastosowanie oraz sposoby oparte na ich zastosowaniu PL364825A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0107822.9A GB0107822D0 (en) 2001-03-28 2001-03-28 Sapogenin derivatives their synthesis and use methods based upon their use
PCT/GB2002/001578 WO2002079221A2 (en) 2001-03-28 2002-03-28 Sapogenin derivatives, their synthesis and use

Publications (1)

Publication Number Publication Date
PL364825A1 true PL364825A1 (pl) 2004-12-27

Family

ID=9911795

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02364825A PL364825A1 (pl) 2001-03-28 2002-03-28 Pochodne sapogeniny, ich synteza i zastosowanie oraz sposoby oparte na ich zastosowaniu

Country Status (24)

Country Link
US (1) US20040147495A1 (pl)
EP (1) EP1383787B1 (pl)
JP (1) JP2004525945A (pl)
KR (1) KR20040007479A (pl)
CN (1) CN1678325A (pl)
AR (2) AR033079A1 (pl)
AT (1) ATE416185T1 (pl)
AU (1) AU2002242894B2 (pl)
BR (1) BR0208533A (pl)
CA (1) CA2442150A1 (pl)
CZ (1) CZ20032620A3 (pl)
GB (1) GB0107822D0 (pl)
HR (1) HRP20030770A2 (pl)
IL (1) IL158115A0 (pl)
MX (1) MXPA03008800A (pl)
NO (1) NO20034364L (pl)
NZ (1) NZ529136A (pl)
PE (1) PE20021042A1 (pl)
PL (1) PL364825A1 (pl)
RU (1) RU2311423C2 (pl)
TR (2) TR200301613T2 (pl)
UA (1) UA78696C2 (pl)
WO (1) WO2002079221A2 (pl)
ZA (2) ZA200307478B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
CA2477787C (en) * 2002-03-27 2011-12-20 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
KR20080031062A (ko) * 2002-03-27 2008-04-07 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
MXPA05004494A (es) * 2002-10-28 2005-07-26 Phytopharm Plc Reduccion estereoespecifica de sapogen-3-onas.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
GB0424528D0 (en) * 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CN101768202B (zh) * 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
WO2012010896A1 (en) 2010-07-20 2012-01-26 Phytopharm Plc Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
TWI422378B (zh) * 2010-11-18 2014-01-11 Univ Chung Shan Medical 使用薯蕷皂素來改善與停經期症候群有關聯的認知缺陷
ES2951664T3 (es) 2011-09-08 2023-10-24 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
PL3461834T3 (pl) 2013-03-13 2021-12-27 Sage Therapeutics, Inc. Neuroaktywne steroidy
KR101480982B1 (ko) * 2013-03-20 2015-02-03 (주)셀인바이오 골형성 유도 화합물 및 이의 응용
CN104177469A (zh) * 2013-05-28 2014-12-03 江苏柯菲平医药有限公司 一种知母中菝葜皂苷元衍生物的制备方法
CN104324038B (zh) * 2013-07-24 2018-11-06 四川京华创生物科技有限公司 一种薯蓣皂苷元-3-位衍生物的用途
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3319612T (lt) 2015-07-06 2021-08-25 Sage Therapeutics, Inc. Oksisteroliai ir jų naudojimo būdai
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MX2019003724A (es) 2016-09-30 2019-09-04 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CN110267966B (zh) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
IL293231A (en) 2016-10-18 2022-07-01 Sage Therapeutics Inc Oxysterols and methods of using them
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
SG50585A1 (en) * 1990-01-18 1998-07-20 Cura Nominees Pty Ltd Glycoalkaloids
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
AU4226593A (en) * 1992-06-26 1994-01-24 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
EP0696292A1 (en) * 1993-04-28 1996-02-14 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
WO1995018143A1 (en) * 1993-12-28 1995-07-06 Pfizer Inc. Hypocholesterolemic agents
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
CA2198097A1 (en) * 1994-08-30 1996-03-07 Douglas J. Allen Spirostanyl glycosidal crystals
CA2200436A1 (en) * 1994-09-20 1996-04-04 Pfizer Inc. Combination therapy for hypercholesterolemia
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
US6178679B1 (en) * 1996-02-13 2001-01-30 David M. Dundorf Weather-proof readerboard signage system
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
CN1245982C (zh) * 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
IL138664A0 (en) * 1998-03-26 2001-10-31 Phytopharm Plc Smilagenin and anzurogenin-d for the treatment of alheimer's disease
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Also Published As

Publication number Publication date
WO2002079221A3 (en) 2003-04-17
US20040147495A1 (en) 2004-07-29
ZA200407460B (en) 2009-09-30
RU2003131883A (ru) 2005-05-10
IL158115A0 (en) 2004-03-28
CA2442150A1 (en) 2002-10-10
KR20040007479A (ko) 2004-01-24
CN1678325A (zh) 2005-10-05
ZA200307478B (en) 2009-04-29
JP2004525945A (ja) 2004-08-26
EP1383787B1 (en) 2008-12-03
ATE416185T1 (de) 2008-12-15
RU2311423C2 (ru) 2007-11-27
NO20034364L (no) 2003-11-28
BR0208533A (pt) 2004-04-20
WO2002079221A2 (en) 2002-10-10
MXPA03008800A (es) 2004-10-15
GB0107822D0 (en) 2001-05-23
TR200700134T1 (tr) 2007-02-21
CZ20032620A3 (cs) 2004-04-14
UA78696C2 (en) 2007-04-25
AR040402A1 (es) 2005-04-06
HRP20030770A2 (en) 2005-08-31
EP1383787A2 (en) 2004-01-28
NZ529136A (en) 2005-12-23
PE20021042A1 (es) 2002-11-19
NO20034364D0 (no) 2003-09-29
AU2002242894B2 (en) 2008-08-21
AR033079A1 (es) 2003-12-03
TR200301613T2 (tr) 2004-08-23

Similar Documents

Publication Publication Date Title
ZA200307478B (en) Sapogenin derivatives, their synthesis and use
HRP20040027A2 (en) 1-phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
HRP20030472A2 (en) Methanesulphonamido-benzofuran, preparation methodand use thereof as synthesis intermediate
HUP0401648A3 (en) 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
EP1385868A4 (en) STEROID DERIVATIVES
EP1254140A4 (en) SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
HK1074444A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
HRP20050142A2 (en) Steroid conjugates, preparation thereof and the use thereof
EP1551790A4 (en) MONOACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, THEIR PREPARATION AND THEIR USE
HUP0600238A2 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
EP1392317A4 (en) SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
IL159064A0 (en) New phenylalkyloxy- phenyl derivatives
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
PL365342A1 (pl) Pochodne mikanolidu, ich wytwarzanie i zastosowania terapeutyczne
HK1077823A1 (en) Acutumine and acutumine compounds, synthesis and use
IL157793A0 (en) Caloporoside derivatives, methods for the production thereof and their use
HK1065792A1 (en) 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
SI1372670T1 (en) Caloporoside derivatives, methods for the production thereof and their use

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)